Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis

Business Wire April 5, 2016

Ironwood Pharmaceuticals to Present Clinical and Preclinical Data on sGC Stimulators at Upcoming Scientific Conferences

Business Wire March 30, 2016

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Business Wire March 23, 2016

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

Business Wire March 9, 2016

Ironwood Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference

Business Wire March 1, 2016

Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS® (linaclotide)

Business Wire February 29, 2016

Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C

Business Wire February 24, 2016

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update

Business Wire February 18, 2016

Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701

Business Wire February 18, 2016

Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference

Business Wire February 17, 2016

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2015 Investor Update Call

Business Wire February 4, 2016

Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company

Business Wire January 11, 2016

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Business Wire January 4, 2016

Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan

Business Wire November 30, 2015

Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Business Wire November 30, 2015

Ironwood Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference

Business Wire November 4, 2015

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Business Wire November 3, 2015

Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701

Business Wire November 3, 2015

Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

Business Wire November 2, 2015

Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries

PR Newswire October 27, 2015